Toronto, Canada – The Board of Directors of Arch Biopartners, Inc., (Arch or the Company) (TSX Venture: ACH and OTCBB: FOIFF) approved the grant of 300,000 stock options (the “Options”) to its Directors, as disclosed in the Company’s quarterly filings of August 29, 2016. The Options were granted as compensation for serving as Directors for a one-year term commencing at the date of the last annual meeting of shareholders, March 30, 2016. Each of the six Directors was granted 50,000 Options exercisable into common shares at $0.50 per share, for a period of five years.
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.
Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections; MetaMx, which targets elusive brain tumor initiating cells; Metablok, a potential treatment for sepsis and cancer metastasis; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease biofilm on various medical grade metals and plastics.
For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies, please visit
www.archbiopartners.com
For more information, please contact:
Richard Muruve
CEO and Director
Arch Biopartners, Inc.
647-428-7031
info@archbiopartners.com
Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.